InMed Pharmaceuticals ( (INM) ) has provided an announcement.
InMed Pharmaceuticals Inc. announced the selection of an intravitreal formulation for INM-089, aimed at treating dry age-related macular degeneration (AMD). The formulation has demonstrated successful delivery and a favorable pharmacokinetic profile at doses up to ten times the projected therapeutic level, which indicates a significant safety margin. This development marks a critical step in addressing the major unmet medical need for treatments of dry AMD, which affects a substantial portion of the global population.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs.
YTD Price Performance: -35.83%
Average Trading Volume: 488,905
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.23M
For detailed information about INM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com